LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
XBIO
Xenetic Biosciences, Inc.
There isn't enough reported data to score XBIO yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
XBIO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
XBIO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
XBIO PE Valuation
XBIO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
XBIO Forward outlook
There aren't enough analyst estimates for XBIO to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over XBIO on earnings quality, reporting a profit while its opponent remains loss making.
XBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.51 |
| Q2 2026 | -$1.15 | +$0.85 |
| Q1 2026 | -$1.19 | +$1.19 |
| Q4 2025 | -$1.58 | +$0.99 |
| Q3 2025 | -$2.05 | +$0.57 |
| Q2 2025 | -$2.00 | +$1.03 |
| Q1 2025 | -$2.38 | +$0.51 |
| Q4 2024 | -$2.57 | +$0.14 |
XBIO is still losing money, but far less than before: $1.54 per share over the past year, against $17.00 at its worst in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over XBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over XBIO on profitability, with a higher operating margin.
XBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $725.3K | -29% |
| Q2 2026 | $660.6K | +12% |
| Q1 2026 | $806.9K | +36% |
| Q4 2025 | $766.3K | +18% |
| Q3 2025 | $1M | +67% |
| Q2 2025 | $589.9K | -19% |
| Q1 2025 | $593.3K | +16% |
| Q4 2024 | $648.8K | -3.4% |
XBIO's revenue fell from its 2025 peak and has held roughly level since: $725,257 last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -240% | -187 points |
| Q2 2026 | -147% | -24 points |
| Q1 2026 | -62% | +97 points |
| Q4 2025 | -81% | +88 points |
| Q3 2025 | -53% | +28 points |
| Q2 2025 | -123% | +61 points |
| Q1 2025 | -159% | +90 points |
| Q4 2024 | -169% | +18 points |
XBIO's operating margin was −240% last quarter, down 187 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over XBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
XBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$662.1K | -$3.9K |
| Q2 2026 | -$875.5K | -$491.7K |
| Q1 2026 | -$536.4K | +$465.5K |
| Q4 2025 | -$242.7K | +$431.3K |
| Q3 2025 | -$658.2K | -$199.2K |
| Q2 2025 | -$383.8K | +$141.3K |
| Q1 2025 | -$1M | +$157.5K |
| Q4 2024 | -$674K | +$119K |
XBIO has burned cash in almost every quarter: −$2M over the past year, against −$3M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over XBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
XBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +48.8K shares |
| 1 year | +52% | +801K shares |
| 3 years | +54% | +818K shares |
| 5 years | +168% | +1.5M shares |
| Available history | +276% | +1.7M shares |
XBIO has 2M diluted shares, up 52% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
XBIO Net Leverage
XBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
XBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 8.3 | Oversold |
XBIO's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
XBIO PE vs Healthcare Sector
XBIO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over XBIO on trend strength, trading above more of its moving averages.
XBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.01 | 17% below |
| 20 week MA | $2.74 | 39% below |
| 50 week MA | $2.72 | 39% below |
| 100 week MA | $3.06 | 46% below |
| 200 week MA | $3.54 | 53% below |
XBIO is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over XBIO on returns for 2026, with the stronger performance.
XBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.3 | $21.9 | +53% |
| 2021 | $21.9 | $14.4 | -34% |
| 2022 | $14.4 | $3.10 | -78% |
| 2023 | $3.10 | $3.45 | +11% |
| 2024 | $3.45 | $4.11 | +19% |
| 2025 | $4.11 | $2.08 | -49% |
| 2026 YTD | $2.08 | $1.66 | -20% |
XBIO has finished lower in three of the last six years. It's down 20% so far in 2026.